Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacyCNBC • Wednesday
Hims & Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive HealthBusiness Wire • Wednesday
Hims & Hers Stock Just Plummeted 17%. Is the Stock a Buy Ahead of a Peptide Push?The Motley Fool • 11/13/26
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on ItZacks Investment Research • 11/13/26
HIMS Q3 Earnings Call Highlights Marketing Reset and Margin PressureZacks Investment Research • 11/10/26
Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady24/7 Wall Street • 11/10/26
Hims & Hers Celebrated Its Eli Lilly Deal, Then Lost a Quarter of Its Value in a Week24/7 Wall Street • 11/10/26
Hims & Hers Just Warned Investors for the Third Time This Year. CEO Andrew Dudum Calls the Subscriber Losses a Trade He'll Make ‘Every Time'24/7 Wall Street • 11/10/26